In a deal worth up to $100 million, Micromet Inc. licensed the preclinical anti-angiogenesis monoclonal antibody D93 to privately held Tracon Pharmaceuticals Inc. (BioWorld Today)

Tracon Licenses D93 Antibody From Micromet

March 19, 2007

By Trista Morrison

No Comments

In a deal worth up to $100 million, Micromet Inc. licensed the preclinical anti-angiogenesis monoclonal antibody D93 to privately held Tracon Pharmaceuticals Inc. (BioWorld Today)

Pfizer, Biogen Idec Launch Incubators To Build Pipelines

March 19, 2007

By Trista Morrison

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Articles by Trista Morrison

Cannasat and IntelGenx Expand Cannabinoid-Based Collaboration

Cannasat and IntelGenx Expand Cannabinoid-Based Collaboration

Cleveland BioLabs Raises $30M, Pursues DOD Contract

Intarcia Is Re-Born With $50M Series BB Financing

Intarcia Is Re-Born With $50M Series BB Financing

Cleveland BioLabs Raises $30M, Pursues DOD Contract

Pfizer, Biogen Idec Launch Incubators To Build Pipelines

Tracon Licenses D93 Antibody From Micromet

Tracon Licenses D93 Antibody From Micromet

Pfizer, Biogen Idec Launch Incubators To Build Pipelines

Today's news in brief

Today's news in brief

J&J’s Ottava robotic system approved for US pivotal trial

‘Evo’ AI can design complete genomes

Medtronic receives CE mark for next generation Endoflip system